Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 15

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 15
---
 PTK7 is a clinically validated ADC target with broad solid tumor expression, particularly in tumor-initiating cells. A Phase 1/2 clinical study of GEN1107 in advanced solid tumors is recruiting.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 10/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
GEN1057 – Bispecific antibody with potential in solid tumors

• Bispecific antibody targeting FAPα and DR4, created using Genmab’s DuoBody technology platform

• Phase 1/2 clinical trial (NCT06573294) in malignant solid tumors is recruiting

GEN1057 (DuoBody-FAPαxDR4) is a bispecific antibody-based investigational medicine created using Genmab’s DuoBody technology platform. GEN1057 is designed for the conditional DR4 transactivation-mediated tumor cell killing by crosslinking FAPα expression on cancer-associated fibroplasts with DR4 expressed on tumor cells. A Phase 1/2 clinical trial of GEN1057 in malignant solid tumors is recruiting.

#### Second Quarter 2025 Update
• April: Poster presentation at the 2025 Annual Meeting of the AACR, “DuoBody-FAPαxDR4 induces tumor cell death through FAPα-dependent, DR4 transactivation-mediated apoptosis.”

#### GEN1286 – ADC with potential in solid tumors
• ADC that targets EGFR and cMet being evaluated in advanced solid tumors

• Phase 1/2 clinical trial (NCT06685068) in advanced solid tumors is recruiting

GEN1286 is an ADC targeting EGFR and cMet, two validated cancer targets created using Genmab’s ADC technology. A Phase 1/2 clinical study of GEN1286 in advanced solid tumors is recruiting.

#### Preclinical Programs
• Broad preclinical pipeline that includes both partnered products and in-house programs based on our proprietary technologies and/or antibodies

• Multiple new Investigational New Drug (IND) applications expected to be submitted over the coming years

• Genmab has entered multiple strategic collaborations to support the expansion of our innovative pipeline, including our acquisition of ProfoundBio in 2024

Our preclinical pipeline includes immune effector function enhanced antibodies developed